Researchers Find Mesothelioma Survival Advantage in Adding Amatuximab...

Scientists say patients with unresectable pleural mesothelioma who are going through chemotherapy may live longer if treated with the monoclonal antibody amatuximab.(PRWeb March 05, 2016)Read the full story at http://www.prweb.com/releases/2016/03/prweb13249708.htm (Source: PRWeb: Medical Pharmaceuticals)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

from MedWorm: Mesothelioma http://medworm.com/index.php?rid=168949645&cid=c_409_34_f&fid=22564&url=http%3A%2F%2Fwww.prweb.com%2Freleases%2F2016%2F03%2Fprweb13249708.htm